Crescita Therapeutics Inc. announced that Laboratoires FILLMED ("FILLMED") has submitted a New Medical Device License (MDL) application for the ART FILLER® range of products. Crescita and FILLMED entered into an agreement in January 2020, granting Crescita the exclusive rights to distribute the ART-FILLER injectables product range and the New Cellular Treatment Factor® (NCTF®) in Canada. The ART FILLER is an exclusive collection of five hyaluronic acid (HA)-based fillers. Since it was developed in 2016, healthcare professionals including dermatologists and plastic surgeons outside Canada have used it to create or restore the volumes and contours of the face, to temporarily eliminate superficial-to-deep wrinkles and facial folds, and to augment and volumize the lips. The ART-FILLER range of products were submitted for approval by Health Canada as Class III medical devices. Due to backlogs created by the COVID-19 pandemic, it is estimated that the average target review time for a Class III MDL application may take as long as 6-9 months. In 2018, the dermal filler market in North America was worth approximately USD 1.6 billion. Driven by the growing demand for innovative and advanced dermal fillers, the region is expected to lead the estimated 7.8% CAGR for the global market through to 2026. The Company is planning to launch FILLMED's NCTF products onto the Canadian market in the first half of 2021, while it anticipates launching the ART-FILLER range imminently following its approval by Health Canada by late 2021 or early 2022.